MIRA Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
MIRA Pharmaceuticals's earnings have been declining at an average annual rate of -56.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Key information
-56.4%
Earnings growth rate
-24.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -391.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How MIRA Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -12 | 7 | 2 |
| 31 Dec 23 | 0 | -12 | 7 | 2 |
| 30 Sep 23 | 0 | -8 | 5 | 2 |
| 30 Jun 23 | 0 | -6 | 4 | 2 |
| 31 Mar 23 | 0 | -7 | 5 | 2 |
| 31 Dec 22 | 0 | -7 | 5 | 2 |
| 31 Mar 22 | 0 | -4 | 2 | 1 |
| 31 Dec 21 | 0 | -2 | 1 | 1 |
Quality Earnings: MIRA is currently unprofitable.
Growing Profit Margin: MIRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MIRA is unprofitable, and losses have increased over the past 5 years at a rate of 56.4% per year.
Accelerating Growth: Unable to compare MIRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: MIRA has a negative Return on Equity (-391.51%), as it is currently unprofitable.